Allene M. Diaz - Jul 15, 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Allene M. Diaz
Stock symbol
IONS
Transactions as of
Jul 15, 2024
Transactions value $
-$81,019
Form type
4
Date filed
7/17/2024, 05:02 PM
Previous filing
Jul 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +4.68K +36.9% $0.00 17.4K Jul 15, 2024 Direct F1
transaction IONS Common Stock Sale -$44K -900 -5.19% $48.94 16.5K Jul 16, 2024 Direct F2, F3
transaction IONS Common Stock Sale -$37K -737 -4.48% $50.17 15.7K Jul 16, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Restricted Stock Unit Options Exercise $0 -4.68K -53.41% $0.00 4.08K Jul 15, 2024 Common Stock 4.68K $0.00 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 3, 2023
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.745 to $49.461 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.0825 to $50.245 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
F5 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F6 Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.